Skip to content
AnalystLens

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Oct 20, 2026)

Reports
Leadership Changes
Filing Date
Filed October 20, 2026
Period End
October 20, 2026
Security
VRTX
In the record · 2016–202610-K1110-Q328-K100

VRTX filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 100 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Mar ’17Mar ’17
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Material agreement8-K · Apr ’21Apr ’21
  4. Leadership change8-K · Aug ’25Aug ’25

01—Abstract

Summary

Summary of the 8-K filed October 20, 2026. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals Incorporated (VRTX) announced a significant addition to its Board of Directors on October 20, 2026, with the appointment of Daniel Brennan.

This appointment increases the size of the Board from ten to eleven members. Mr. Brennan brings a wealth of financial expertise, having served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation until his retirement in June 2025, and holding various senior finance roles there for many years prior. His extensive background in financial leadership is expected to be a valuable asset to Vertex's strategic and financial oversight.

In addition to his extensive corporate finance experience, Mr. Brennan has a strong track record of public company board service, currently sitting on the boards of Waters Corporation and Madrigal Pharmaceuticals, and previously serving on Nuance Corporation's board. His appointment to the Audit and Finance Committee will further strengthen the board's financial governance. The company also disclosed that Mr. Brennan received a $400,000a restricted stock unit award upon joining, which is set to vest in October 2027, aligning his interests with long-term shareholder value.

02—Key points

Key Highlights

  1. Vertex Pharmaceuticals appointed Daniel Brennan to its Board of Directors on October 20, 2026.
  2. The board size has been increased from ten to eleven members to accommodate the new director.
  3. Mr. Brennan brings extensive financial experience, including his recent role as EVP, CFO of Boston Scientific Corporation.
  4. He has also been appointed to the Company's Audit and Finance Committee.
  5. Mr. Brennan possesses prior public company board experience with Waters Corporation, Madrigal Pharmaceuticals, and Nuance Corporation.
  6. Upon appointment, Mr. Brennan received a $400,000 restricted stock unit award vesting in October 2027.

03—Questions

Frequently Asked Questions

  1. Who is Daniel Brennan and why was he appointed to the board?

    Daniel Brennan is a seasoned financial executive with extensive experience, notably serving as the Executive Vice President and Chief Financial Officer of Boston Scientific Corporation. He was appointed to Vertex's Board of Directors to leverage his financial acumen and board experience to enhance the company's governance and strategic oversight, particularly within the Audit and Finance Committee.

  2. How does this appointment affect the size of the board?

    The appointment of Daniel Brennan has increased the size of Vertex's Board of Directors from ten to eleven members.

  3. What is the compensation for Mr. Brennan's appointment?

    Upon joining the Board on October 20, 2026, Mr. Brennan was awarded $400,000 in restricted stock units, which are scheduled to vest in October 2027. This award aligns his compensation with the long-term performance and value of the company.

  4. Does Mr. Brennan have any conflicts of interest or undisclosed related-party transactions with Vertex?

    Based on the filing, there are no disclosed transactions involving the Company and Mr. Brennan that would require reporting under Item 404(a) of Regulation S-K. Furthermore, his appointment was not based on any arrangement or understanding with other individuals that needed disclosure.

04—Continue

← View all 8-K filings